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A B S T R A C T
We present the 55-year old woman who has had kidney transplantation three times. She has been treated with immu-
nosuppressive therapy and lamivudine for hepatitis B and C. Nine years after the last transplantation she showed neuro-
logical symptoms that presented in the form of confusion and epileptic seizures of the grand mal type. A brain MRI
showed large oval zones of hyperintense MR signal in T2- weighted image and hypointense in T1- weighted image
around the frontal horns of the lateral ventricles, bilaterally and in both cerebellar hemispheres. After reduction in
immunosuppression and the exclusion of lamivudine from therapy, the patient was stable with normal neurological sta-
tus during the course of next five years. We start from the assumption that the concomitant use of cyclosporin with
mycophenolate mofetil and lamivudine, despite normal concentrations of cyclosporin, might cause the accumulation of
toxic metabolites and lead to neurotoxicity that mimics PML in a chronic viral environment.
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Introduction
Progressive multifocal leukoencephalopathy (PML) is
a rapidly progressive degenerative demyelinating disease
that occurs in immunocompromised patients. The dis-
ease was initially identified as a rare complication of
chronic lymphocytic leukemia and Hodgkin’s disease.
Later PML was reported in association with other leuke-
mias and lymphomas, cancer chemotherapy, immuno-
suppression as well as with chronic inflammatory dis-
eases including AIDS. PML is a progressive condition,
although prolonged survival and clinical remission have
been described in both AIDS-related and non-AIDS-re-
lated diseases.
The disease was initially identified by Astrom and col-
leagues as a rare complication of chronic lymphocytic
leukemia and Hodgkin’s disease1. Subsequent cases were
reported in association with other leukemias and lym-
phomas, with cancer chemotherapy, with immunosup-
pression for rheumatic disease or after organ transplan-
tation, and with chronic inflammatory diseases such as
sarcoid, tuberculosis, or nontropical sprue2. It is now es-
timated that 4% of all patients with AIDS will develop
PML3.
Suspicion of progressive multifocal leukoencephalo-
pathy is aroused by characteristic clinical and neuro-
radiologic abnormalities in an immunocompromised pa-
tient. Aphasia, dementia, and confusional states are typi-
cal manifestations.
In PML, neuroimaging studies demonstrate abnor-
malities of the cerebral or cerebellar white matter (hypo-
dense white matter by computerized tomography and
high-signal intensity of white matter by T2-weighted
MRI). These abnormalities represent demyelinating le-
sions in the deep white matter4.
In our case we present a specific therapeutic approach
in which a reduction in immunosuppresion, despite of
the risk or kidney rejection, may bring to a recovery of
cerebral functions.
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Case Report
A 55-year old female patient hospitalized in the De-
partment of Neurology (November, 2001) with clinical
signs of grand mal seizures. Heteroanamnestic data sho-
wed she had memory impairment and disordered behav-
ior, developed in a period of three months. She was ner-
vous, confused and forgetful. She had difficulty with
dressing herself and suffered of disorientation in time, as
well as insomnia. She experienced some neuralgic symp-
toms of low limb weakness and dizziness. She was afe-
brile all the time.
According to the patient’s medical history she suf-
fered from chronic glomerulonephritis. She developed
chronic renal failure at the age of 33 and was treated
with chronic hemodialysis. In this period she became B
virus hepatitis positive.
Renal transplantation was performed in 1980 from a
living donor (her sister). Seven months later, graft failure
developed due to renal artery stenosis. Later, in 1988, she
underwent a cadaveric renal transplantation. Unfortu-
nately, renal vein thrombosis developed, and the kidney
transplant was removed on the ninth postoperative day.
In 1992 cadaveric renal transplantation was performed
again. After that transplantation she became C virus pos-
itive.
The immunosuppressive regimen during the course of
six years after transplantation included azathioprine,
cyclosporin and prednisone. After that period azathio-
prine was replaced with mofetil mycophenolate due to
the worsening of hepatal function. Consequently, lamivu-
dine was additionally included in the therapy.
From then on she began taking mofetil mycopheno-
late (Cell-Cept) 500 mg twice daily, cyclosporin (Sandim-
mun Neoral) 75 mg twice daily (2.5 mg/kg/day), predni-
sone (Decortin) 10 mg, lamivudine 100 mg daily, nifedi-
pine 5 mg twice daily, atenolol 25 mg.
The therapy did not change for the next three years,
except for a reduction in the lamivudine dose to 150 mg
intermittently during the last six months before admis-
sion to the neurology department.
In the nine years after transplantation she had a reac-
tivation of CMV twice, and Herpes zoster a year prior to
hospitalization.
On admission in the Department of Neurology, in No-
vember 2001, the patient exhibited clinical signs of
grand-mal seizures. Diazepam was given intravenously.
A general physical examination was normal and no nu-
chal rigidity was present. Her pupils were normally reac-
tive with forced deviation of the eyes to the left. No disor-
ders of facial nerves were discovered. Motor examination
showed no weakness in the upper and lower extremities,
but muscle tone was decreased and tendon reflexes were
attenuated. Plantar responses were normal. Clouding of
consciousness was diagnosed.
The neurological therapy that followed included car-
bamazepine 200 mg twice daily. Her condition improved,
and she was free of seizures.
Urgent evaluation by CT of the head found hypodense
white matter lesions with no intravenous contrast en-
hancement, located at both frontal regions as well as in
the white matter of the cerebellum. These changes were
assigned as multifocal leukoencephalopathy.
A brain MRI at admission showed large oval zones of
hyperintense MR signal in T2- weighted image and hypo-
intense in T1- weighted image in both cerebellar hemi-
spheres, around the frontal horns of the lateral ventri-
cles, bilaterally. In the left hemisphere, frontally, cortical
changes were found, i.e. hyperintense MR signal in T2-
weighted image and hypointense in T1-weighted image.
There were no gadolinium contrast imbibitions in these
particular zones (Figure 1).
An EEG was arrhythmic with signs of paroxysmal
changes in the frontal regions, more emphasized at the
right side. Her fundus examination was normal.
On the Folstein Mini Mental Status she scored 30/32.
The laboratory data, obtained at admission are pre-
sented in Tables 1 and 2. Cyclosporin concentration was
67.3 ng/mL (cyclosporin whole blood, FPIA-Abbot) and
serum level of carbamazepine 11.7 ng/mL.
Genome detection of polyomavirus JC from cerebro-
spinal liquor (PCR) as well as detection of HHV6 and
CMV (PCR) were found negative. Serology for toxoplas-
mosis and human immunodeficiency virus (HIV1/2) were
negative, while hepatitis B and C remained positive.
Based on the above evidence we decided to reduce the
immunosuppression for the patient. Mofetil mycophe-
nolate was discontinued, and the cyclosporin dose was
slightly tapered to 50 mg twice daily. Furthermore, lami-
vudine was excluded from therapy on the grounds that it
may cause adverse reactions like peripheral neuropathy,
dizziness, insomnia and other sleep disorders, as well as
depression (especially when administered in combina-
tion).
Additionally, the patient had a mild amylase eleva-
tion, which may be an adverse reaction of lamivudine.
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Fig. 1. Brain MRI at admission: Large oval zones of hyperin-
tense MR signal in T2- weighted image.
After being discharged from the hospital, the pa-
tient’s condition improved; she slept better and her walk
was more stable. Due to the development of toxic hepati-
tis in the next month, carbamazepine had to be gradually
excluded as well, leading to an improvement of hepatic
function in the next six months.
Two years later control MRI showed extensive atro-
phy of the parenchyma in the frontal and, to a lesser ex-
tent, in the parietal regions with widened deep sulci.
There were no new lesions in the remaining white mat-
ter compared to the previous MRI findings (Figure 2).
In the follow up period of five years, she has shown no
more epileptic attacks (or other neurological disorders)
except for some psychomotorical slowness.
Discussion
Progressive multifocal leukoencephalopathy (PML)
usually occurs in an immunocompromised individual, pu-
tatively attributable to reactivation of a latent JC virus.
The onset of PML may be insidious. Presenting signs
and symptoms include impaired speech, memory loss,
changes in mentation, and visual disturbance. Visual
field loss (homonymous hemianopsia) and motor weak-
ness, progressing to hemiparesis, are common findings5.
Patients remain afebrile during the course of the illness.
The cerebrospinal fluid is virtually always normal, al-
though there may be a slight elevation in the protein
level or cell count.
Our patient showed similar neurological symptoms
which we believed were related to the effects of immuno-
suppressive therapy (cyclosporin, micophenolate mofetil
and prednisolon), as well as possibly of lamivdine, in the
conditions of the chronic viral infection.
The host and viral factors that lead to the develop-
ment of PML are not clearly understood. Over 70 percent
of adults carry antibodies to JC virus, and JC virus has
been shown to persist in kidneys and to be shed in urine2.
JC virus is a polyomavirus. It was first isolated in 1971,
when brain tissue from a patient with PML was inocu-
lated into cell culture derived from a fetal brain6. The
pathogenesis of infection is unclear, but the virus proba-
bly enters the body through the respiratory tract. JC virus
appears to target the kidneys as the main site of infection
and remains latent for the lifetime of the individual5,7.
Reactivation, leading to PML, occurs in immunocom-
promised individuals. Recent studies indicate that the
presence of JC virus in cerebrospinal fluid, as identified
by the polymerase chain reaction (PCR), has high speci-
ficity for the diagnosis of active disease8,9.
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Fig. 2. After two years, control radiological finding of brain
MRI: Extensive atrophy of parenchyma was found in frontal and
in lesser extent in parietal regions with widened deep sulci.
In our patient genome detection of polyomavirus JS
from cerebrospinal liquor (PCR) was found negative,
therefore the diagnosis of PML was not probable. A de-
finitive diagnosis of PML is made by brain biopsy, but our
patient did not agree to this procedure.
Some authors believe that PML should be considered
as one of the possible extrahepatic manifestations of
HCV infection too10. Furthermore, some earlier sources
state that progressive dementia, with or without focal
abnormalities or seizures, may be related to progressive
multifocal leukoencephalopathy due to infections with
other viruses, including herpes simplex virus, CMV, and
EBV; and occasionally to demyelination or other toxic ef-
fects of cyclosporine or tacrolimus11. There is a report of
cyclosporin neurotoxicity after doxorubicin chemother-
apy for lymphoproliferative disease after transplanta-
tion12. In this case the authors proposed that an impaired
blood-brain barrier from long-term use of cyclosporin en-
abled doxorubicin to produce neurotoxicity. Some au-
thors suggested that, despite normal concentrations of
cyclosporin, its metabolism may have been affected by a
concomitant high dose chemotherapy (as evidenced by a
raised alanine aminotransferase concentration), leading
to the accumulation of toxic metabolites; these could
damage the blood-brain barrier and cause neurotoxici-
ty13.
The clinical and radiological features of cyclosporin
neurotoxicity after chemotherapy are consistent with the
posterior leukoencephalopathy syndrome. The reversible
posterior leukoencephalopathy syndrome is associated
with headaches, vomiting, confusion, seizures, visual dis-
turbance, and motor signs, in various degrees. Neuro-
imaging typically shows bilateral, often strikingly sym-
metrical, white matter changes in the posterior regions
of the cerebral hemispheres, particularly the occipital
lobes and the posterior parietal lobes. The clinical and ra-
diological findings usually resolve within two to three
weeks if the underlying cause is removed14.
Neuroradiological findings in our patient may fit this
syndrom only partially.
Conclusions
Five years later, after the appearance of first neuro-
logical disorders, the patient is stable, with normal neu-
rological status and no progression on MRI brain exami-
nation. There was a deterioration of renal function after
the reduction of immunosuppression, and she began
haemodialysis treatment.
There are no previous reports of neurotoxicity associ-
ated with hepatitis B and C viruses and the type of che-
motherapy regimen that our patient used. Consequently,
we started from the assumption that the concomitant
use of cyclosporin with mycophenolate mofetil and lami-
vudine, despite normal concentrations of cyclosporin,
might cause the accumulation of toxic metabolites and
lead to neurotoxicity that mimics PML in a chronic viral
environment.
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NEUROTOKSI^NOST KOJA OPONA[A PROGRESIVNU MULTIFOKALNU
LEUKOENCEFALOPATIJU U BOLESNICE S TRANSPLANTIRANIM BUBREGOM
S A @ E T A K
Prikazali smo 55 godina staru bolesnicu kojoj je u tri navrata ura|ena transplantacija bubrega. Uz imunosupresivnu
terapiju, lije~ena je lamivudinom zbog hepatitisa B i C. Devet godina nakon posljednje transplantacije, bolesnica je
postala smetena i konfuzna, a potom je dobila epilepti~ki napadaj tipa grand mal. Nalaz MR mozga je pokazao velike
ovalne zone hiperintenzivne u T2 mjerenom vremenu i hipointenzivne u T1 mjerenom vremenu oko frontalnih rogova
lateralnih mo`danih komora obostrano, te u cerebelarnim hemisferama. Ubrzo nakon smanjenja imunosupresije i
isklju~enja lamivudina iz terapije, bolesnica se neurolo{ki stabilizirala i u razdoblju od slijede}ih pet godina nije imala
epilepti~kih napadaja. Ovakav klini~ki tijek mo`e se objasniti pretpostavkom da je istovremena primjena imuno-
supresiva i lamivudina u uvjetima kroni~ne virusne infekcije, uzrokovala nakupljanje toksi~nih metabolita i izazvala
neurotoksi~nost koja sli~i progresivnoj multifokalnoj leukoencefalopatiji.
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